195 related articles for article (PubMed ID: 35308500)
1. Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT.
Tanaka A; Sekine T; Ter Voert EEGW; Zeimpekis KG; Delso G; de Galiza Barbosa F; Warnock G; Kumita SI; Veit Haibach P; Huellner M
Front Med (Lausanne); 2022; 9():796085. PubMed ID: 35308500
[TBL] [Abstract][Full Text] [Related]
2. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of baseline
Reyes Marlés RH; Navarro Fernández JL; Puertas García-Sandoval JP; Santonja Medina F; Mohamed Salem L; Frutos Esteban L; Contreras Gutiérrez JF; Castellón Sánchez MI; Ruiz Merino G; Claver Valderas MA
Eur J Hybrid Imaging; 2021 Sep; 5(1):16. PubMed ID: 34476632
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.
Zwezerijnen GJC; Eertink JJ; Ferrández MC; Wiegers SE; Burggraaff CN; Lugtenburg PJ; Heymans MW; de Vet HCW; Zijlstra JM; Boellaard R
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):486-493. PubMed ID: 36166080
[TBL] [Abstract][Full Text] [Related]
6. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
Im HJ; Kim YK; Kim YI; Lee JJ; Lee WW; Kim SE
Nucl Med Mol Imaging; 2013 Mar; 47(1):36-43. PubMed ID: 24895506
[TBL] [Abstract][Full Text] [Related]
8. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
10. Correlation of
Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
[TBL] [Abstract][Full Text] [Related]
11. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
12. The Evaluation of Preoperative
Vural Topuz Ö; Aksu A; Erinç SR; Tokgözoğlu N; Tamam MÖ
Mol Imaging Radionucl Ther; 2022 Feb; 31(1):16-22. PubMed ID: 35114747
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of
Zheng F; Wanjun X; Shuaishuai W; Tong W; Lue Z
Med Int (Lond); 2021; 1(5):23. PubMed ID: 36698530
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
[TBL] [Abstract][Full Text] [Related]
17. Utility of [
Sa R; Liu D; Zhao H; Hou S; Lin Q; Guan F
Front Med (Lausanne); 2020; 7():281. PubMed ID: 32766257
[No Abstract] [Full Text] [Related]
18. Assessment of Mediastinal Tumors Using SUV
Morita T; Tatsumi M; Ishibashi M; Isohashi K; Kato H; Honda O; Shimosegawa E; Tomiyama N; Hatazawa J
Asia Ocean J Nucl Med Biol; 2017; 5(1):22-29. PubMed ID: 28840135
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
20. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
